Intranasal Drug Delivery Devices Market Report 2026

Intranasal Drug Delivery Devices Market Overview

• Intranasal Drug Delivery Devices market size has reached to $65.09 billion in 2025 • Expected to grow to $99.11 billion in 2030 at a compound annual growth rate (CAGR) of 8.8% • Growth Driver: Rising Prevalence of Chronic Diseases Fuels Growth In The Intranasal Drug Delivery Devices Market • Market Trend: Innovative Intranasal Drug Delivery Technology • North America was the largest region in 2025.

What Is Covered Under Intranasal Drug Delivery Devices Market?

Intranasal drug delivery devices are medical devices that deliver medications into the nasal cavity. These devices are intended to administer medications directly to the nasal mucosa, which is highly vascularized and has a huge surface area, allowing the drug to be absorbed into the bloodstream quickly. It delivers drugs or therapeutic substances in various forms, including sprays, powders, or liquid solutions, directly into the nasal cavity. The main products in intranasal drug delivery devices are powder delivery devices, liquid delivery devices, pressurized metered-dose inhalers and others. A powder delivery device refers to a type of medical or pharmaceutical device designed to administer medications. It includes unit-dose and multi-dose and is used in various applications such as chronic obstructive pulmonary disease (COPD), rhinitis, cystic fibrosis, nasal congestion, asthma and others. The end users are hospitals, clinics, homecare, and others.

What Is The Intranasal Drug Delivery Devices Market Growth Forecast?

The intranasal drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $99.11 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to increasing development of biologics and vaccines via nasal delivery, rising demand for homecare drug administration, expansion of intranasal delivery for neurological therapies, growing investments in advanced drug-device combinations, increasing focus on patient compliance solutions. Major trends in the forecast period include increasing adoption of precision nasal delivery systems, rising demand for non-invasive drug administration, growing development of multi-dose nasal devices, expansion of patient-friendly drug delivery formats, enhanced focus on rapid drug absorption.

What Is The Driver Of The Intranasal Drug Delivery Devices Market?

The increasing prevalence of chronic diseases is expected to propel the growth of the intranasal drug delivery devices market going forward. Chronic diseases can be defined as conditions that last 1 year or more and require ongoing medical attention, limit activities of daily living, or both. Intranasal drug delivery devices are used to manage chronic diseases by providing a non-invasive and efficient way to administer medications. They allow medications to be delivered directly to the affected area, which is convenient, making it easy to use and promoting rapid absorption. For instance, in June 2024, according to the National Health Service, a UK-based government department, in 2023, the number of individuals in England at risk of developing type 2 diabetes has risen to 3,615,330, up from 3,066,330 in 2022, with over half a million (549,000) additional people identified with non-diabetic hyperglycemia, or pre-diabetes. Therefore, the increasing prevalence of chronic diseases is driving the growth of the intranasal drug delivery devices industry.

Key Players In The Global Intranasal Drug Delivery Devices Market

Major companies operating in the intranasal drug delivery devices market are Johnson and Johnson Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline Plc, 3M Company, Becton Dickinson and Company, Teva Pharmaceutical Industries Ltd., AptarGroup Inc., West Pharmaceutical Services Inc., Recipharm AB, Nemera Development S.A., Consort Medical plc., Vectura Group plc., OptiNoset Inc., Flamel Technologies, Aegis Therapeutics LLC, PendoPharm Inc., Kurve Technology Inc., Impel NeuroPharma, Impexium Medical Products, ENT Technologies Pty. Ltd., Neurelis Inc.

Global Intranasal Drug Delivery Devices Market Trends and Insights

Major companies are operating in the intranasal drug delivery devices market, focusing on developing new and improved products such as recyclable polyolefin nasal spray actuator to enhance sustainability, improve patient compliance, and support environmentally friendly drug delivery solutions. Recyclable polyolefin nasal spray actuator refers to a nasal drug delivery component made entirely from polyolefin materials, designed for multiple-dose administration without metal parts. For instance, in January 2023, Aptar Pharma, a US-based drug delivery and pharmaceutical solutions company, launched the APF Futurity, the first metal-free multidose nasal spray pump designed to address the growing need for highly recyclable packaging. APF Futurity is made entirely from polyolefin materials, contains no metal components, and has a Class AA highly recyclable certification from cyclos-HTP. The pump delivers precise and consistent dosing with gentle actuation, is compatible with nasal saline and other over-the-counter formulations, and supports sustainable recycling making it ideal for environmentally conscious drug delivery solutions and patient convenience.

What Are Latest Mergers And Acquisitions In The Intranasal Drug Delivery Devices Market?

In January 2024, Kindeva Drug Delivery, a US-based provider of drug–device combination product development and manufacturing, acquired Summit Biosciences Inc. for an undisclosed amount. With this acquisition, Kindeva aims to expand its drug-delivery platform by adding specialized intranasal formulation and manufacturing capabilities, enabling it to serve biopharma clients across a broader range of complex combination products. Summit Biosciences Inc. is a US-based contract development and manufacturing organization focused on intranasal drug-delivery solutions.

What Defines the Intranasal Drug Delivery Devices Market?

The intranasal drug delivery devices market consists of sales of nasal sprays, nasal powder devices, nasal antipsychotic medications, nasal epinephrine devices, nasal drops, and nasal inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Intranasal Drug Delivery Devices Market Report 2026?

The intranasal drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the intranasal drug delivery devices industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.